Acute Ischemic Stroke - Pipeline Review, H1 2015

Published: Apr, 2015 | Pages: 113 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Acute Ischemic Stroke - Pipeline Review, H1 2015

Summary 

Global Markets Direct's, 'Acute Ischemic Stroke - Pipeline Review, H1 2015', provides an overview of the Acute Ischemic Stroke's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Ischemic Stroke and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Ischemic Stroke
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Acute Ischemic Stroke and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Acute Ischemic Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Ischemic Stroke pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason To Buy 

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute Ischemic Stroke
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute Ischemic Stroke pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Acute Ischemic Stroke Overview 9
Therapeutics Development 10
Pipeline Products for Acute Ischemic Stroke - Overview 10
Pipeline Products for Acute Ischemic Stroke - Comparative Analysis 11
Acute Ischemic Stroke - Therapeutics under Development by Companies 12
Acute Ischemic Stroke - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Acute Ischemic Stroke - Products under Development by Companies 17
Acute Ischemic Stroke - Companies Involved in Therapeutics Development 19
AB Science 19
AstraZeneca PLC 20
Biogen, Inc. 21
D-Pharm Ltd. 22
Daiichi Sankyo Company, Limited 23
DiaMedica Inc. 24
Digna Biotech, S.L. 25
Genervon Biopharmaceuticals, LLC 26
Glucox Biotech AB 27
Grifols, S.A. 28
Lumosa Therapeutics Co., Ltd. 29
Mitsubishi Tanabe Pharma Corporation 30
Pharmicell Co., Ltd. 31
PhytoHealth Corporation 32
Remedy Pharmaceuticals, Inc. 33
Simcere Pharmaceutical Group 34
Stemedica Cell Technologies, Inc. 35
Acute Ischemic Stroke - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Target 37
Assessment by Mechanism of Action 39
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
3K3A-APC - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Cerecellgram-Stroke - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
DB-017 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
DM-199 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
DS-1040 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
glyburide - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
GM-602 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
HBN-1 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Human Plasmin - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
LT-3001 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
masitinib - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Mesenchymal Stem Cells - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
MP-124 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
natalizumab - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
PHN-014 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Recombinant Plasmin - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
SIM-071201 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
THR-18 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
ticagrelor - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Acute Ischemic Stroke - Recent Pipeline Updates 77
Acute Ischemic Stroke - Dormant Projects 100
Acute Ischemic Stroke - Discontinued Products 102
Acute Ischemic Stroke - Product Development Milestones 105
Featured News & Press Releases 105
Mar 19, 2015: DiaMedica to Present at the 12th Annual BIO Asia International Conference 105
Dec 18, 2014: D-Pharm Achieves Primary End-point in Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated With tPA 105
Nov 04, 2014: D-Pharm Reports First Results from its Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated with tPA 106
Aug 19, 2014: US Department of Justice Closes Investigation into PLATO Clinical Trial for BRILINTA 106
Jun 02, 2014: D-Pharm Reports Completion of the Second Dose Tier in its Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated with the Thrombolytic Drug tPA 107
Apr 22, 2014: ZZ Biotech Announces Phase 2 Trial with 3K3A-APC in Stroke; Funds Will Be Provided by NIH and Broadview Ventures 107
Mar 04, 2014: D-Pharm reports the successful interim analysis of its Phase 2 clinical study of THR-18 in acute stroke patients 109
Jan 21, 2014: D-Pharm completes recruitment of patients into the first dosage tier of its Phase 2 study with THR-18 in acute stroke patients treated with tPA 109
Jan 08, 2014: D-Pharm receives grant to support the development of its Phase 2 product, THR-18 110
Dec 05, 2013: AstraZeneca announces initiation of two additional global studies for BRILINTA 110
Appendix 112
Methodology 112
Coverage 112
Secondary Research 112
Primary Research 112
Expert Panel Validation 112
Contact Us 112
Disclaimer 113

List of Tables

Number of Products under Development for Acute Ischemic Stroke, H1 2015 10
Number of Products under Development for Acute Ischemic Stroke - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Comparative Analysis by Late Stage Development, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Development by Companies, H1 2015 (Contd..1) 18
Acute Ischemic Stroke - Pipeline by AB Science, H1 2015 19
Acute Ischemic Stroke - Pipeline by AstraZeneca PLC, H1 2015 20
Acute Ischemic Stroke - Pipeline by Biogen, Inc., H1 2015 21
Acute Ischemic Stroke - Pipeline by D-Pharm Ltd., H1 2015 22
Acute Ischemic Stroke - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 23
Acute Ischemic Stroke - Pipeline by DiaMedica Inc., H1 2015 24
Acute Ischemic Stroke - Pipeline by Digna Biotech, S.L., H1 2015 25
Acute Ischemic Stroke - Pipeline by Genervon Biopharmaceuticals, LLC, H1 2015 26
Acute Ischemic Stroke - Pipeline by Glucox Biotech AB, H1 2015 27
Acute Ischemic Stroke - Pipeline by Grifols, S.A., H1 2015 28
Acute Ischemic Stroke - Pipeline by Lumosa Therapeutics Co., Ltd., H1 2015 29
Acute Ischemic Stroke - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 30
Acute Ischemic Stroke - Pipeline by Pharmicell Co., Ltd., H1 2015 31
Acute Ischemic Stroke - Pipeline by PhytoHealth Corporation, H1 2015 32
Acute Ischemic Stroke - Pipeline by Remedy Pharmaceuticals, Inc., H1 2015 33
Acute Ischemic Stroke - Pipeline by Simcere Pharmaceutical Group, H1 2015 34
Acute Ischemic Stroke - Pipeline by Stemedica Cell Technologies, Inc., H1 2015 35
Assessment by Monotherapy Products, H1 2015 36
Number of Products by Stage and Target, H1 2015 38
Number of Products by Stage and Mechanism of Action, H1 2015 40
Number of Products by Stage and Route of Administration, H1 2015 42
Number of Products by Stage and Molecule Type, H1 2015 44
Acute Ischemic Stroke Therapeutics - Recent Pipeline Updates, H1 2015 77
Acute Ischemic Stroke - Dormant Projects, H1 2015 100
Acute Ischemic Stroke - Dormant Projects (Contd..1), H1 2015 101
Acute Ischemic Stroke - Discontinued Products, H1 2015 102
Acute Ischemic Stroke - Discontinued Products (Contd..1), H1 2015 103
Acute Ischemic Stroke - Discontinued Products (Contd..2), H1 2015 104